CLAIMS

1. A compound, which is a salt of 1-[[(3S)-3-methyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid, wherein

   (i) the salt is mono(4-hydroxybenzoate),

   (ii) the salt is mono-tryptophan salt, or

   (iii) the salt is a hemisuccinate.

2. The compound according to claim 1(i), which is in crystal form.

3. The compound according to claim 2,

   (i) wherein the crystal has, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of at least 6.9 ±0.2, 12.8 ±0.2, 13.9 ±0.2, and 24.7 ±0.2 degrees, optionally having, in a powder X-ray diffraction spectrum, no diffraction peak at diffraction angles (2θ) of 11.3±0.2 and 14.4±0.2 degrees;

   or

   (ii) wherein the crystal has, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of at least 5.4±0.2, 6.9±0.2, 13.9±0.2, 18.1±0.2, 19.4±0.2, 19.8±0.2, 20.9±0.2, and 24.7±0.2 degrees, optionally having, in a powder X-ray diffraction spectrum, no diffraction peak at diffraction angles (2θ) of 11.3±0.2 and 14.4±0.2 degrees.

4. The compound according to claim 2 or 3,

(i) wherein the crystal has, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of 5.4±0.2, 6.9±0.2, 10.3±0.2, 12.8±0.2, 13.9±0.2, 15.0±0.2, 15.3±0.2, 15.9±0.2, 16.6±0.2, 16.8±0.2, 18.1±0.2, 19.4±0.2, 19.8±0.2, 20.9±0.2, 21.8±0.2, 22.7±0.2, 23.6±0.2, 24.7±0.2, 25.4±0.2, 25.8±0.2, 26.3±0.2, 26.7±0.2, 27.6±0.2, 27.8±0.2, 30.3±0.2, 33.4±0.2, and 34.2±0.2 degrees; and/or

(ii) wherein the crystal is characterized by a powder X-ray diffraction spectrum chart shown in Fig. 7; and/or

(iii) wherein the crystal has an endothermic peak with an onset temperature of 150±2°C or a peak temperature of 153±2°C in differential scanning calorimetry; and/or

(iv) wherein the crystal is characterized by a differential scanning calorimetry chart shown in Fig. 8.

5. The compound according to claim 2, wherein the crystal has, in a powder X-ray diffraction spectrum, a diffraction peak at a diffraction angle (2θ) of at least 11.3±0.2 degrees.

6. The compound according to claim 2 or claim 5,

(i) wherein the crystal has, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of at least 5.6±0.2, 11.3±0.2, 13.2±0.2, 15.9±0.2, 16.9±0.2, 18.8±0.2, 22.7±0.2, and 24.2±0.2 degrees; and/or

(ii) wherein the crystal has, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of 5.6±0.2, 7.0±0.2, 7.9±0.2, 11.3±0.2, 12.3±0.2, 13.2±0.2, 13.9±0.2, 15.9±0.2, 16.9±0.2, 17.4±0.2, 17.9±0.2, 18.4±0.2, 18.8±0.2, 19.4±0.2, 19.9±0.2, 20.4±0.2, 21.0±0.2, 21.2±0.2, 21.9±0.2, 22.7±0.2, 23.2±0.2, 23.4±0.2, 24.2±0.2, 25.2±0.2, 26.5±0.2, 27.5±0.2, 29.1±0.2, 29.8±0.2, 30.5±0.2, and 34.1±0.2 degrees; and/or

(iii) wherein the crystal is characterized by a powder X-ray diffraction spectrum chart shown in Fig. 9; and/or

(iv) wherein the crystal has an endothermic peak with an onset temperature of 154±2°C or a peak temperature of 158±2°C in differential scanning calorimetry; and/or

(v) wherein the crystal is characterized by a differential scanning calorimetry chart shown in Fig. 10.

7. The compound according to claim 1(ii), which is in crystal form.

8. The compound according to claim 7,

(i) wherein the crystal has, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of at least 8.0±0.2, 9.7±0.2, 16.0±0.2, 17.0±0.2, 18.9±0.2, 19.1±0.2, 22.2±0.2, and 24.6±0.2 degrees; and/or

(ii) wherein the crystal has, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of 8.0±0.2, 9.7±0.2, 12.8±0.2, 15.6±0.2, 16.0±0.2, 16.6±0.2, 17.0±0.2, 17.3±0.2, 17.6±0.2, 18.2±0.2, 18.6±0.2, 18.9±0.2, 19.1±0.2, 19.6±0.2, 20.9±0.2, 21.3±0.2, 21.7±0.2, 21.9±0.2,

22.2±0.2, 22.6±0.2, 23.4±0.2, 23.8±0.2, 24.6±0.2, 25.3±0.2, 25.7±0.2, 26.2±0.2, 26.6±0.2, 27.1±0.2, 27.4±0.2, 27.9±0.2, 28.2±0.2, 28.7±0.2, 29.1±0.2, 29.9±0.2, 30.2±0.2, 30.9±0.2, 32.0±0.2, 32.2±0.2, 32.5±0.2, 33.1±0.2, 34.1±0.2, 34.5±0.2, and 34.8±0.2 degrees; and/or

(iii) wherein the crystal is characterized by a powder X-ray diffraction spectrum chart shown in Fig. 15; and/or

(iv) wherein the crystal has an endothermic peak with an onset temperature of 178±2°C or a peak temperature of 183±2°C in differential scanning calorimetry; and/or

(v) wherein the crystal has an exothermic peak with an onset temperature of 185±2°C or a peak temperature of 187±2°C in differential scanning calorimetry; and/or

(vi) wherein the crystal is characterized by a differential scanning calorimetry chart shown in Fig. 16.

9. The compound according to claim 1(iii), which is in crystal form.

10. The compound according to claim 9,

(i) wherein the crystal has, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of at least 6.4±0.2, 6.9±0.2, 12.9±0.2, 13.8±0.2, 17.2±0.2, 18.1±0.2, 19.3±0.2, 23.9±0.2, and 24.3±0.2 degrees; and/or

(ii) wherein the crystal has, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of 6.1±0.2, 6.4±0.2, 6.9±0.2, 12.9±0.2, 13.8±0.2, 16.6±0.2, 17.2±0.2, 18.1±0.2, 18.3±0.2, 18.7±0.2, 19.3±0.2, 19.9±0.2, 20.5±0.2, 20.7±0.2, 21.0±0.2, 21.4±0.2, 21.9±0.2, 22.1±0.2,

22.7±0.2, 23.0±0.2, 23.6±0.2, 23.9±0.2, 24.3±0.2, 24.6±0.2, 25.2±0.2, 25.8±0.2, 26.0±0.2, 27.4±0.2, 27.5±0.2, 27.8±0.2, 28.7±0.2, 29.5±0.2, 30.2±0.2, 30.5±0.2, 30.8±0.2, 31.3±0.2, 31.7±0.2, 32.3±0.2, 32.5±0.2, 33.8±0.2, 34.1±0.2, 34.5±0.2, and 34.9±0.2 degrees; and/or

(iii) wherein the crystal is characterized by a powder X-ray diffraction spectrum chart shown in Fig. 17; and/or

(iv) wherein the crystal having an endothermic peak with an onset temperature of 111±2°C or a peak temperature of 114±2°C in differential scanning calorimetry; and/or

(v) wherein the crystal has an endothermic peak with an onset temperature of 137±2°C or a peak temperature of 140±2°C in differential scanning calorimetry; and/or

(vi) wherein the crystal is characterized by a differential scanning calorimetry chart shown in Fig. 18.

11. A compound, which is a crystal of 1-[[(3S)-3-methyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid,

(i) wherein the crystal has, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of at least 6.5±0.2, 7.8±0.2, 8.6±0.2, and 11.6±0.2 degrees; and/or

(ii) wherein the crystal has, in a powder X-ray diffraction spectrum, diffraction peaks at diffraction angles (2θ) of 6.5±0.2, 7.8±0.2, 8.6±0.2, 11.6±0.2, 13.0±0.2, 13.1±0.2, 15.2±0.2, 15.8±0.2, 17.0±0.2, 17.3±0.2, 18.8±0.2, 18.9±0.2, 19.3±0.2, 20.9±0.2, 21.1±0.2, 21.3±0.2, 22.8±0.2, 23.3±0.2, 23.6±0.2, 23.8±0.2, 24.0±0.2, 24.9±0.2, 25.8±0.2, 26.4±0.2, 27.1±0.2,

27.9±0.2, 29.8±0.2, 30.4±0.2, 30.7±0.2, 31.6±0.2, 32.0±0.2, and 34.0±0.2 degrees; and/or

(iii) wherein the crystal is characterized by a powder X-ray diffraction spectrum chart shown in Fig. 1; and/or

(iv) wherein the crystal has an endothermic peak with an onset temperature of 128±2°C or a peak temperature of 133±2°C in differential scanning calorimetry; and/or

(v) wherein the crystal is characterized by a differential scanning calorimetry chart shown in Fig. 2.

12. A pharmaceutical composition comprising the compound according to any one of claims 1 to 11 and a pharmaceutically acceptable carrier.

13. Use of the compound according to any one of claims 1 to 11 in the manufacture of a medicament for the prevention and/or treatment of a neurodegenerative disease, optionally wherein the neurodegenerative disease is multiple system atrophy or Parkinson's disease.

14. The compound according to any one of claims 1 to 11 for use in therapy.